

Medical Drug Clinical Criteria

Subject: Abraxane (paclitaxel, protein bound)
Document #: CC-0099
Status: Revised
Publish Date: ~~03/27/2023~~04/01/2024
Last Review Date: ~~02/24/2023~~02/23/2024

Table of Contents

[Overview](#) [Coding](#) [References](#)
[Clinical criteria](#) [Document history](#)

Overview

This document addresses the use of protein/albumin bound paclitaxel (Abraxane). Abraxane is a taxane primarily used to treat breast cancer, pancreatic cancer, and non-small cell lung cancer.

The FDA approved indications for Abraxane include:

- Metastatic breast cancer after failure of combination chemotherapy or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Non-small cell lung cancer (NSCLC) as first line treatment of locally advanced or metastatic NSCLC in combination with carboplatin in those who are not candidates for curative surgery or radiation therapy.
- Adenocarcinoma of the pancreas as first line therapy of metastatic disease in combination with gemcitabine

The National Comprehensive Cancer Network® (NCCN) provides additional recommendations with a category 1 or 2A level of evidence for the following:

- Hypersensitivity to solvent based taxanes
 - Use in the treatment of taxane responsive cancers when there is incidence of solvent-based taxane hypersensitivity including in NSCLC, endometrial cancers, breast cancers and solid tumors (including Kaposi sarcoma, ovarian cancer including epithelial, ovarian, fallopian tube, and primary peritoneal cancer)
- Melanoma (Uveal or cutaneous)
 - Use as single agent therapy for metastatic or unresectable disease
 - Second-line therapy or subsequent therapy as single agent or in combination with carboplatin for metastatic or unresectable disease
- Pancreatic cancer
 - Use in combination with gemcitabine and cisplatin, but not after resection, in locally advanced or metastatic pancreatic cancer when used as first-line therapy or continuation therapy
 -
- NSCLC
 - Systemic therapy:
 - For recurrent, advanced, or metastatic disease with ECOG 0-1 and no contraindications to PD-1 or PD-L1 inhibitors in combination with atezolizumab and carboplatin for nonsquamous histology, carboplatin and pembrolizumab for squamous histology, or tremelimumab-actl, durvalumab, and carboplatin.
 - For recurrent, advanced, or metastatic disease as first-line therapy for PD-L1 expression tumors that are negative for actionable molecular biomarkers and no contraindications to PD-1 or PD-L1 inhibitors and performance status 0-2 in combination with pembrolizumab and carboplatin for squamous histology, in combination with carboplatin and atezolizumab for nonsquamous histology, or in combination with tremelimumab-actl, durvalumab, and carboplatin for squamous histology.
 - Treatment for recurrent, advanced, or metastatic disease
 - In combination with carboplatin (PS 0-2)
 - As single agent for PS 2 or subsequent therapy (if not already given)
- Ovarian cancer
 - Use for ovarian cancer in the treatment of persistent or recurrent ovarian cancer
- Cervical cancer
 - Second-line or subsequent therapy as a single agent for local/regional recurrence, stage IVB or recurrence, or persistent, recurrent, or metastatic small NECC (cell neuroendocrine carcinoma of the cervix)
- Biliary tract cancers
 - Primary or subsequent treatment in combination with gemcitabine for unresectable or R2 (resected gross residual) disease or metastatic disease
- Breast cancer
 - First-line therapy in combination with pembrolizumab or second line/subsequent therapy (if PD-1/PD-L1 inhibitor has not

- been previously used) for PD-L1 positive triple negative recurrent unresectable or stage IV disease.
 - First-line therapy (if no germline BRCA 1/2 mutation), second line (if not a candidate for fam trastuzumab deruxtecan-nxki), or third line therapy as single agent therapy or in combination with carboplatin for recurrent unresectable, or stage IV HER2-negative HR+ with visceral crisis or endocrine therapy refractory disease.
 - First line therapy (if no germline BRCA 1/2 mutation and if PD-L1 CPS < 10), second line therapy, or third-line therapy as single agent therapy or in combination with carboplatin for recurrent unresectable, or stage IV triple negative breast cancer.
 - Fourth-line therapy and beyond in combination with trastuzumab for HER2-positive recurrent unresectable or stage IV that is HR negative or HR positive with or without endocrine therapy.
 - May be substituted for other taxanes (paclitaxel or docetaxel) in select patients due to medical necessity (ie, hypersensitivity reaction)
- Uterine /Endometrial Carcinoma
 - Second-line or subsequent therapy as a single agent for recurrent disease.
- Ampullary adenocarcinoma
 - Use as first-line agent in metastatic ampullary adenocarcinoma specifically for pancreatobiliary/mixed type in combination with gemcitabine if ECOG status 0-2
 - Use as subsequent therapy in those with ECOG score of 0 to 1 in combination with gemcitabine for pancreatobiliary/mixed type disease.
- Small Bowel adenocarcinoma
 - Use as a single agent or in combination with gemcitabine for advanced or metastatic small bowel adenocarcinoma as
 - initial therapy or
 - as subsequent therapy in those who previously received initial therapy with a PD-1 inhibitor (nivolumab with or without ipilimumab, pembrolizumab, or dostarlimab-gxly) (Aldrich, 2018; Overman, 2018)

Abraxane label includes a black box warning restricting use in patients with baseline neutrophil counts of less than 1,500 cells/mm³, and frequent peripheral blood cell counts should be performed to monitor for bone marrow suppression.

Additionally, protein-bound paclitaxel received 2A recommendations for use in invasive inflammatory and special consideration breast cancer. NCCN Breast cancer guidelines support for this use followed that sequential single agents are preferred but chemotherapy combinations may be used in select individuals with high tumor burden, rapidly progressing disease and visceral crisis.

Abraxane also received a recommendation for use as a second-line or subsequent therapy as a single agent for cervical cancer, as local/regional recurrence, stage IVB or distant metastases, or persistent, recurrent, or metastatic small cell neuroendocrine carcinoma of the cervix (NECC). NCCN previously provided a 2B recommendation for this use but updated their compendia to 2A. NCCN cited the same data (Alberts 2012 trial) an open-label phase 2 study which enrolled 35 patients. The study included those with persistent or recurrent carcinoma of the cervix with disease progression and treated them with Abraxane. The overall survival was 9.4 months and progression-free survival was 5 months. Twenty-five patients discontinued due to disease progression.

Other Uses

Protein-bound paclitaxel has been studied or is currently being studied as a single agent or in combination with other chemotherapeutic agents for the treatment of other cancers, including use in adrenocortical cancer (Demeure, 2012), advanced solid tumors (Abu-Khalaf, 2015), angiosarcoma (Hirata, 2011), cancer of unknown primary (CUP), cervical cancer (Alberts, 2012; Li, 2017), esophageal cancer (Fan, 2016; Shi, 2013), gastric cancer (Koizumi, 2015), head and neck cancer (including squamous-cell carcinoma of the esophagus, hypopharynx, nasopharyngeal, oropharynx, and oral cavity) (Adkins, 2013; Adkins, 2016; Damascelli, 2007; Huang, 2016), hepatocellular cancer, cholangiocarcinoma (Sahai 2018), prostate cancer (Shepard, 2009), small cell lung cancer (Grilley-Olson, 2015), urothelial cancer (Ko, 2013), and AIDS-related Kaposi Sarcoma (Fortino, 2016). Limitations of some of these studies include lack of a randomized comparator group and small study populations.

To date, the FDA has not approved protein-bound paclitaxel for use in the treatment of any of these conditions. NCCN also gives a category 2A recommendation for use of Abraxane in combination with atezolizumab, carboplatin, and with or without bevacizumab as first line therapy in those with NSCLC and BRAF or NTRK positive tumors in certain circumstances; however, published data is lacking. Additionally, the NCCN NSCLC guideline discussion emphasizes the importance of targeted therapies in individuals with specific oncogenic drivers (i.e., EGFR, ALK, ROS1, BRAF, NTRK).

Definitions and Measures

Adenocarcinoma: Cancer originating in cells that line specific internal organs and that have gland-like (secretory) properties.

Adjuvant therapy: Treatment given after the primary treatment to increase the chances of a cure; may include chemotherapy, radiation, hormone or biological therapy.

Chemotherapy: Medical treatment of a disease, particularly cancer, with drugs or other chemicals.

ECOG or Eastern Cooperative Oncology Group Performance Status: A scale and criteria used by doctors and researchers to assess how an

individual's disease is progressing, assess how the disease affects the daily living abilities of the individual, and determine appropriate treatment and prognosis. This scale may also be referred to as the WHO (World Health Organization) or Zubrod score which is based on the following scale:

- 0 = Fully active, able to carry on all pre-disease performance without restriction
- 1 = Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, for example, light house work, office work
- 2 = Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours
- 3 = Capable of only limited self-care, confined to bed or chair more than 50% of waking hours
- 4 = Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair
- 5 = Dead

Line of Therapy:

- First-line therapy: The first or primary treatment for the diagnosis, which may include surgery, chemotherapy, radiation therapy or a combination of these therapies.
- Second-line therapy: Treatment given when initial treatment (first-line therapy) is not effective or there is disease progression.
- Third-line therapy: Treatment given when both initial (first-line therapy) and subsequent treatment (second-line therapy) are not effective or there is disease progression.

Locally advanced cancer: Cancer that has spread only to nearby tissues or lymph nodes.

Malignant: Cancerous. Malignant cells can invade and destroy nearby tissue and spread to other parts of the body.

Melanoma: A type of cancer that begins in the melanocytes. Melanoma is also referred to as malignant melanoma and cutaneous melanoma.

Microtubule inhibitors (MTI): A class of drugs including taxanes, vinca alkaloids, and epothilones that stabilize or destabilize microtubules, thereby suppressing microtubule dynamics required for proper mitotic function, effectively blocking cell cycle progression and resulting in cell death.

Non-small cell lung cancer: A group of lung cancers that are named for the kinds of cells found in the cancer and how the cells look under a microscope. The three main types of non-small cell lung cancer are squamous cell carcinoma, large cell carcinoma, and adenocarcinoma.

One line of therapy: Single line of therapy.

Refractory Disease: Illness or disease that does not respond to treatment.

Relapse or recurrence: After a period of improvement, during which time a disease (for example, cancer) could not be detected, the return of signs and symptoms of illness or disease. For cancer, it may come back to the same place as the original (primary) tumor or to another place in the body.

Taxane: A type of mitotic inhibitor and antimicrotubule drug used to treat cancer that blocks cell growth by stopping mitosis (cell division).

Unresectable: Unable to be removed with surgery.

Clinical Criteria

When a drug is being reviewed for coverage under a member's medical benefit plan or is otherwise subject to clinical review (including prior authorization), the following criteria will be used to determine whether the drug meets any applicable medical necessity requirements for the intended/prescribed purpose.

Abraxane (paclitaxel, protein bound)

Requests for Abraxane (paclitaxel, protein bound) may be approved for the treatment of any of the following indications:

- I. ~~Relapsed or metastatic breast cancer when the following criteria are met (NCCN2A):~~
 - A. ~~Used as a single agent; AND~~
 - B. ~~Used in a single line of therapy;~~
- OR
- II. ~~Metastatic or unresectable locally advanced breast cancer when the following criteria are met (NCCN 1):~~
 - A. ~~Individual has triple-negative breast cancer, defined as lack of estrogen- and progesterone-receptor expression and no overexpression of HER2; AND~~
 - B. ~~Individual is using in combination with pembrolizumab;~~
- OR
- I. Individual has a diagnosis of Breast Cancer; AND
 - A. Individual is using as a single agent after failure on combination chemotherapy for metastatic disease or

Formatted: No underline

Formatted: No underline

Formatted: Left

relapsed within 6 months of adjuvant therapy (Label); **AND**

1. Individual has had previous chemotherapy including an anthracycline unless clinically contraindicated;

OR

B. Individual has recurrent unresectable or metastatic (stage IV) disease; **AND**

1. Individual has HER2 negative disease (NCCN 2A); **AND**

a. Individual is using as a single agent or in combination with carboplatin; **AND**

b. Disease is hormone receptor-positive and refractory to endocrine therapy or has visceral crisis; **AND**

c. Using in one of the following ways:

i. First line therapy if no germline BRCA 1/2 mutation; **OR**

ii. Second-line therapy if not a candidate for fam trastuzumab deruxtecan-nxki; **OR**

iii. Third-line and beyond;

OR

2. Individual has triple negative breast cancer (NCCN 2A); **AND**

a. Individual has disease with high tumor burden, rapidly progressing disease and visceral crisis; **AND**

b. Individual is using as a single agent or in combination with carboplatin; **AND**

c. Using in one of the following ways:

i. First line therapy if PD-L1 < 10 and no germline BRCA 1/2 mutation; **OR**

ii. Second-line therapy and beyond;

OR

d. Individual has PD-L1 positive, triple-negative disease; **AND**

i. Individual is using in combination with pembrolizumab; **AND**

ii. Using in one of the following ways:

(a) As first line therapy (NCCN 1); **OR**

(b) Second and subsequent line of therapy if PD-1/PD-L1 inhibitor has not been previously used (NCCN 2A);

OR

III.C. Treatment of any breast cancer in an individual with confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity (NCCN 2A);

OR

II. Individual has a diagnosis of recurrent or metastatic cervical cancer (NCCN 2A); **AND**

A. Individual is using as second-line or subsequent therapy; **AND**

B. Individual is using as a single agent;

OR

IV-III. Individual has a diagnosis of Malignant Melanoma when the following criteria are met (NCCN 2A); **AND**

A. Individual is using Used-as;

1. A single agent; **OR**

2. In combination with carboplatin;

AND

B. Individual is using as second line or subsequent therapy; **AND**

C. Individual has an ECOG performance status of 0-2 (Kottschade 2011);

OR

V-IV. Individual has a diagnosis Treatment of recurrent, locally advanced or metastatic NSCLC when the following criteria are met (Label); **AND**

A. Individual is using Used as first-line therapy; **AND**

B. Individual is using Given in combination with carboplatin; **AND**

C. Individual has an ECOG performance status of 0-2 (NCCN 2A);

OR

VI-V. Individual has a diagnosis Treatment of recurrent, advanced, or metastatic NSCLC when the following criteria are met (NCCN 2A); **AND**

A. Individual is using Used as a single agent for first progression after initial systemic therapy (if not already given); **AND**

B. Individual has an ECOG performance status of 0-2;

OR

VII-VI. Individual has a diagnosis Treatment of recurrent, -advanced or metastatic squamous NSCLC when all of the following criteria are met (NCCN 1, 2A); **AND**

A. Individual is using Used as first-line therapy; **AND**

B. Individual is using Given in combination with pembrolizumab and carboplatin; **AND**

C. Individual has a current ECOG performance status of 0-2;

Formatted: No underline

Formatted: Left

Formatted: No underline

Formatted: Left, Indent: Left: 0.75", No bullets or numbering, Tab stops: 0.81", Left + Not at 0.65" + 0.65"

Formatted: No underline

Formatted: Left

Formatted: No underline

Formatted: Left

Formatted: No underline

Formatted

Formatted: No underline

Formatted: No underline

Formatted

Formatted

Formatted: Left

Formatted

Formatted

Formatted

Formatted

Formatted

Formatted

Formatted: No underline

Formatted: No underline

Formatted

Formatted: No underline

Formatted: Font: Bold

Formatted

Formatted: Left

Formatted: Indent: Left: 0.38"

Formatted: No underline

Formatted: Left

Formatted: No underline

Formatted: No underline

Formatted: Font: Bold

Formatted

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font: Bold

Formatted: Font color: Auto

Formatted: Font: Bold

OR
VIII.VII. ~~Individual has a diagnosis~~ Treatment of recurrent, advanced, or metastatic nonsquamous NSCLC ~~when the following criteria are met~~ (NCCN 2A):
A. ~~Individual is using~~Used as first-line therapy; **AND**
B. ~~Individual is using~~Given in combination with atezolizumab and carboplatin; **AND**
C. Individual has an ECOG performance status of 0-2;

OR
VIII. Individual has a diagnosis of recurrent, advanced, or metastatic nonsquamous NSCLC (NCCN 1, 2A); **AND**
A. Individual is using as subsequent therapy after failure of kinase inhibitor targeted agent; **AND**
B. Individual is using in combination with carboplatin and atezolizumab; **AND**
C. Individual has an ECOG performance status of 0-2;

Formatted: Font: Bold

Formatted: Left

OR
IX. ~~Individual has a diagnosis~~ Treatment of recurrent, advanced, or metastatic squamous NSCLC ~~when the following criteria are met~~ (NCCN 2A); **AND**
A. ~~Individual is using~~Used as first line therapy; **AND**
B. Individual has no sensitizing epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genetic tumor aberrations; **AND**
C. Individual is using in combination with tremelimumab-actl, durvalumab, and carboplatin; **AND**
D. Individual has a PD-L1 expression $\geq 1\%$ and less than or equal to 49%; **AND**
E. Individual is not receiving therapy for an autoimmune disease or chronic condition requiring treatment with a systemic immunosuppressant; **AND**
F. Individual has an ECOG performance status of 0-2;

Formatted: Font: Bold

Formatted: Left, No bullets or numbering

Formatted: Font: Bold

OR
X. ~~Treatment of recurrent, advanced, or metastatic nonsquamous NSCLC when the following criteria are met~~ (NCCN 1, 2A):
A. ~~Used as subsequent therapy after failure of kinase inhibitor targeted agent~~; **AND**
B. ~~Given in combination with carboplatin and atezolizumab~~; **AND**
C. ~~Individual has an ECOG performance status of 0-2~~;

OR
XI.X. ~~Treatment of NSCLC in an individual with confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity~~ (NCCN 2A);

OR
XII.XI. Individual has a diagnosis Ovarian Cancer (Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer) ~~when the following criteria are met~~ (NCCN 1, 2A); **AND**
A. ~~Individual is using for~~ Treatment of persistent or recurrent ovarian cancer when used as a single agent (epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer); **OR**
B. ~~Individual is using for the~~ Treatment of persistent or recurrent ovarian cancer when used with carboplatin (epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer) in an individual with confirmed taxane (that is, solvent-base paclitaxel or docetaxel) hypersensitivity;

Formatted: Font: Bold

OR
XIII. ~~Locally advanced or metastatic adenocarcinoma of the pancreas when the following criteria are met~~ (Label, NCCN 1, 2A):
A. ~~Used as first-line therapy or as continuation (maintenance therapy)~~; **AND**
B. ~~Given in combination in one of the following ways~~:
1. ~~With gemcitabine as a single-line of therapy~~; **OR**
2. ~~With gemcitabine and cisplatin~~;

Formatted: Font: Bold

Formatted: Left

OR
XII. Individual has a diagnosis of metastatic adenocarcinoma of the pancreas (Label, NCCN 1, 2A); **AND**
A. Individual is using as first line therapy; **AND**
B. Individual is using in combination in one of the following ways:
1. With gemcitabine as a single-line of therapy; **OR**
2. With gemcitabine and cisplatin;

Formatted: Font: Bold

Formatted: Left

Formatted: Font: Bold

Formatted: Left

Formatted: Font: Bold

Formatted: Left, Indent: Left: 0.33", No bullets or numbering

OR
XIII. Individual has a diagnosis of locally advanced adenocarcinoma of the pancreas (NCCN 2A); **AND**
A. Individual is using as first-line therapy or as continuation (maintenance therapy); **AND**
B. Individual is using in combination with gemcitabine as a single-line of therapy;

Formatted: Font: Bold

Formatted: Font: Bold

OR
XIV. Recurrent, metastatic, or high-risk endometrial cancer in an individual with confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity (NCCN 2A);

Formatted: Left

Formatted: Font: Bold

Formatted: Left, Indent: Left: 0.33", No bullets or numbering

OR

XV. Solid tumors where treatment with a taxane is medically appropriate and the individual has confirmed taxane (that is, solvent-based paclitaxel or docetaxel) hypersensitivity (NCCN 2A);

OR
XVI. Individual has a diagnosis of Advanced or metastatic Small bowel adenocarcinoma, when the following criteria are met (NCCN 2A); **AND**

- A. Individual has Treatment of advanced or metastatic disease; AND
B. Individual is using as a single agent or Given in combination with gemcitabine;

Formatted: Font: Bold

OR
XVII. Individual has a diagnosis of Ampullary adenocarcinoma, when the following criteria are met (NCCN 2A); **AND**

- A. Individual is using Treatment in pancreaticobiliary and mixed type disease; AND
B. Individual is using Given in combination with gemcitabine; AND
C. Individual has an ECOG performance status of 0-2;

Formatted: Font: Bold

Formatted: Font: Bold

OR
XVIII. Individual has a diagnosis of Biliary Tract Cancer (NCCN 2A); AND

- A. Individual is using in unresectable or resected gross residual disease OR metastatic disease; AND
C-B. Individual is using in combination with gemcitabine.

Formatted: Indent: Left: 0.19", No bullets or numbering

Formatted: No underline

Formatted: Left, Indent: Hanging: 0.47"

Formatted: No underline

Formatted: No underline

Abraxane (paclitaxel, protein bound) may not be approved for the following:

- I. Individual has baseline neutrophil count of less than 1,500 cells/mm³ prior to initiation of Abraxane; OR
II. When the above criteria are not met and for all other indications.

Coding

The following codes for treatments and procedures applicable to this document are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement policy. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

HCPCS

J9264	Injection, paclitaxel protein-bound particles, 1 mg [Abraxane]
J9258	Injection, paclitaxel protein-bound particles (Teva)
J9259	Injection, paclitaxel protein-bound particles (American Regent)

ICD-10 Diagnosis

C00.0-C80.2	Malignant neoplasms
C17.0-C17.9	Malignant neoplasm of small intestine
C24.1	Malignant neoplasm of ampulla of Vater
C34.00-C34.92	Malignant neoplasm of bronchus and lung
C50.011-C50.929	Malignant neoplasm of breast
C54.0-C54.9	Malignant neoplasm of endometrium
C56.1-C56.9	Malignant neoplasm of ovary
D00.00-D09.9	In-situ neoplasms
Z85.00-Z85.59	Personal history of malignant neoplasm
Z85.810-Z85.9	Personal history of malignant neoplasm

Document History

Revised: 02/23/2024

Document History:

- 02/23/2024 – Annual review: Update existing criteria for use in breast cancer, pancreatic cancer, and small bowel adenocarcinoma. Add NCCN 2A criteria for use in unresectable or metastatic biliary tract cancer when used in combination with gemcitabine. Add NCCN 2A recommendation for use in cervical cancer as second-line or subsequent therapy in recurrent or metastatic disease. Coding Reviewed: Added HCPCS J9258.

- 02/24/2023 – Annual review: Update existing criteria for use in malignant melanoma and pancreatic cancer from NCCN. Added 2A NCCN criteria for use in small bowel adenocarcinoma, ampullary adenocarcinoma, and recurrent, advanced, or metastatic squamous NSCLC in combination with tremelimumab-actl, durvalumab, and carboplatin. Coding Reviewed: Added HCPCS J9259. Added ICD-10-CM C17.0-C17.9, C24.1.
- 02/25/2022 – Annual review: Update NSCLC criteria with NCCN recommendations. Update references. Coding Reviewed: No changes.
- 09/13/2021 – Select review: Update criteria to remove use with atezolizumab for triple negative breast cancer per FDA withdrawal. Coding reviewed: Extended ICD-10-CM code ranges C34.00-C34.92, C50.011-C50.929, C54.0-C54.9, C56.1-C56.9.
- 05/21/2021 – Select review: Update criteria to allow for use with pembrolizumab for triple negative breast cancer per NCCN. Coding Reviewed: No changes.
- 02/19/2021 – Annual Review: Update NSCLC criteria for use in combination with pembrolizumab and carboplatin. Remove notation regarding confirmation of EGFR, ALK, ROS1, and BRAF mutations that are negative or unknown in NSCLC criteria for consistency. Update references. Coding Reviewed: No changes.
- 05/15/2020 – Select Review: Update NSCLC criteria to include first-line therapy use in recurrent and advanced disease, and confirmation of negative ROS1 and BRAF mutations when using in combination with atezolizumab and carboplatin. Add criteria to allow use as subsequent therapy in NSCLC after failure of targeted agents. Coding reviewed: No changes.
- 02/21/2020 – Annual Review: Update NSCLC criteria to remove use with cisplatin per NCCN update. Update ovarian cancer criteria to add use with carboplatin if individual has solvent-base paclitaxel or docetaxel hypersensitivity. Add baseline neutrophil count threshold in non-approvable criteria per labeled contraindications. Wording and formatting changes. Coding Review: No changes.
- 12/09/2019 – Select Review: Add criteria for metastatic nonsquamous NSCLC in combination with atezolizumab and carboplatin. Coding reviewed: Added ICD-10 DX C34.0-C56.9
- 08/16/2019 – Select Review: Update to clarify single agent use in ovarian cancer. Wording and formatting changes for consistency. Coding Reviewed: No changes.
- 05/17/2019 – Annual Review: Initial review of protein bound paclitaxel (Abraxane); Updated to clarify that use in combination with pembrolizumab for the treatment of NSCLC required that the individual also meet the criteria for pembrolizumab. Coding Reviewed: No changes.

References

1. Abu-Khalaf MM, Baumgart MA, Gettinger SN, et al. Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin-bound paclitaxel in patients with advanced solid tumors. *Cancer*. 2015; 121(11):1817-1826.
2. Adkins D, Ley J, Michel L, et al. Nab-paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma. *Oral Oncol*. 2016; 61:1-7.
3. Adkins D, Ley J, Trinkaus K, et al. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck. *Cancer*. 2013; 119(4):766-773.
4. Alberts DS, Blessing JA, Landrum LM, et al. Phase II trial of nab-paclitaxel in the treatment of recurrent or persistent advanced cervix cancer: a gynecologic oncology group study. *Gynecol Oncol*. 2012; 127(3):451-455.
5. Aldrich JD, Raghav KPS, Varadhachary GR, et al. Retrospective analysis of taxane-based therapy in small bowel adenocarcinoma. *Oncologist*. 2019;24:e384-6.
6. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2024. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
7. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
8. Damascelli B, Patelli G, Ticha V, et al. Feasibility and efficacy of percutaneous transcatheter intraarterial chemotherapy with paclitaxel in albumin nanoparticles for advanced squamous-cell carcinoma of the oral cavity, oropharynx, and hypopharynx. *J Vasc Interv Radiol*. 2007; 18(11):1395-1403.
9. Demeure MJ, Stephan E, Sinari S, et al. Preclinical investigation of nanoparticle albumin-bound paclitaxel as a potential treatment for adrenocortical cancer. *Ann Surg*. 2012; 255(1):140-146.
10. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
11. Fan Y, Jiang Y, Zhou X, et al. Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. *Oncotarget*. 2016; 7(31):50624-50634.
12. Fortino S, Santoro M, Iuliano E, et al. Treatment of Kaposi's Sarcoma (KS) with nab-paclitaxel. *Ann Oncol* 2016;27:suppl_4: iv124.
13. Grilley-Olson JE, Keedy VL, Sandler A, et al. A randomized phase II study of carboplatin with weekly or every-3-week nanoparticle albumin-bound paclitaxel (Abraxane) in patients with extensive-stage small cell lung cancer. *Oncologist*. 2015; 20(2):105-106.
14. Hirata T, Yonemori K, Ando M, et al. Efficacy of taxane regimens in patients with metastatic angiosarcoma. *Eur J Dermatol*. 2011; 21(4):539-545.
15. Huang Y, Liang W, Yang Y, et al. Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-paclitaxel) plus cisplatin as treatment for metastatic nasopharyngeal carcinoma. *BMC Cancer*. 2016; 16:464.
16. Koizumi W, Morita S, Sakata Y. A randomized Phase III trial of weekly or 3-weekly doses of nab-paclitaxel versus weekly doses of Cremophor-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE Trial). *Jpn J Clin Oncol*. 2015; 45(3):303-306.
17. Kottschade LA, Suman VJ, Amatruda T 3rd, et al. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group Study, N057E(1). *Cancer*. 2011; 117(8):1704-1710.
18. Ko YJ, Canil CM, Mukherjee SD, et al. Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study. *Lancet Oncol*. 2013; 14(8):769-776.
19. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 202;4 Updated periodically.

20. Li Y, Zeng J, Huang M, et al. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma. *Cancer*. 2017; 123(3):420-425.
21. NCCN Clinical Practice Guidelines in Oncology™. © 2024 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on December 29, 2022.
 - a. Ampullary adenocarcinoma. V1.2024. Revised December 13, 2023.
 - b. Breast cancer. V5.2023. Revised December 5, 2023.
 - c. Biliary Tract Cancers. V3.2023. Revised November 8, 2023.
 - d. Cervical Cancer V1.2024. Revised September 20, 2023.
 - e. Cutaneous Melanoma. V3.2023. Revised October 27, 2023.
 - f. Kaposi Sarcoma. V1.2024. Revised November 7, 2023.
 - g. Non-Small cell lung cancer. V1.2024. Revised December 21, 2023.
 - h. Ovarian Cancer, including fallopian tube cancer and primary peritoneal cancer. V2.2023. Revised June 2, 2023.
 - i. Pancreatic Adenocarcinoma. V1.2024. Revised December 13, 2023.
 - j. Small Bowel Adenocarcinoma. V1.2024. Revised December 20, 2023.
 - k. Uterine Neoplasms. V1.2024. Revised September 20, 2023.
 - l. Uveal melanoma. V1.2023. Revised May 4, 2023.
22. Overman MJ, Adam L, Raghav K, et al. Phase II study of nab-paclitaxel in refractory small bowel adenocarcinoma and CpG island methylator phenotype (CIMP)-high colorectal cancer. *Ann Oncol*. 2018;29:139-44.
23. Sahai V, Catalano PJ, Zalupski MM, et al. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial. *JAMA Oncol*. 2018;4(12):1707-1712. doi:10.1001/jamaoncol.2018.3277. Available at: <https://jamanetwork.com/journals/jamaoncology/fullarticle/2698042>. Accessed December 29, 2022.
24. Shepard DR, Dreicer R, Garcia J, et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. *J Urol*. 2009; 181(4):1672-1677; discussion 1677.
25. Shi Y, Qin R, Wang ZK, Dai GH. Nanoparticle albumin-bound paclitaxel combined with cisplatin as the first-line treatment for metastatic esophageal squamous cell carcinoma. *Onco Targets Ther*. 2013; 6:585-591.
26. Tecentriq® (atezolizumab) [Product Information]. San Francisco: Genentech, Inc. Accessed on December 29, 2022.
[West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer \(IMpower130\): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2019 Jul;20\(7\):924-937. Epub 2019 May 20.](#)

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

© CPT Only – American Medical Association